NASDAQ:VRAX

Virax Biolabs Group (VRAX) Competitors

$0.38

0.00 (0.00%)

(As of 06/6/2023 ET)

Compare

Today's Range: $0.38
▼
$0.40
50-Day Range: $0.34
▼
$0.70
52-Week Range: $0.34
▼
$29.00

Volume: 126,300 shs
Average Volume: 238,227 shs
Market Capitalization: $5.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Financials Institutional Ownership Headlines SEC Filings Short Interest Social Media

VRAX vs. LHDXQ, LHDX, NAVB, CDIO, SNPX, PHIO, OGEN, AVGR, NBSE, and IGAP

Should you be buying Virax Biolabs Group stock or one of its competitors? The main competitors of Virax Biolabs Group include Lucira Health (LHDXQ), Lucira Health (LHDX), Navidea Biopharmaceuticals (NAVB), Cardio Diagnostics (CDIO), Synaptogenix (SNPX), Phio Pharmaceuticals (PHIO), Oragenics (OGEN), Avinger (AVGR), NeuBase Therapeutics (NBSE), and Integrity Applications (IGAP). These companies are all part of the "medical" sector.

Virax Biolabs Group vs.

Virax Biolabs Group (NASDAQ:VRAX) and Lucira Health (NASDAQ:LHDXQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings, community ranking and profitability.

: In the previous week, Virax Biolabs Group had 2 more articles in the media than Lucira Health. MarketBeat recorded 2 mentions for Virax Biolabs Group and 0 mentions for Lucira Health. Virax Biolabs Group's average media sentiment score of 0.00 equaled Lucira Health's average media sentiment score.
Company Overall Sentiment
Virax Biolabs Group Neutral
Lucira Health Neutral
: 0.5% of Virax Biolabs Group shares are held by institutional investors. Comparatively, 57.0% of Lucira Health shares are held by institutional investors. 45.1% of Virax Biolabs Group shares are held by company insiders. Comparatively, 30.4% of Lucira Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
: Virax Biolabs Group has higher earnings, but lower revenue than Lucira Health.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Virax Biolabs Group $5.76 thousand 1,036.47 -$1.71 million N/A N/A
Lucira Health $93.06 million 0.02 -$64.83 million -$3.58 -0.02
: Virax Biolabs Group and Lucira Health both received 0 outperform votes by MarketBeat users.
Company Underperform Outperform
Virax Biolabs Group N/A N/A
Lucira Health N/A N/A
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Virax Biolabs Group
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Lucira Health
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Virax Biolabs Group has a net margin of 0.00% compared to Lucira Health's net margin of -67.54%. Virax Biolabs Group's return on equity of 0.00% beat Lucira Health's return on equity.
Company Net Margins Return on Equity Return on Assets
Virax Biolabs Group N/A N/A N/A
Lucira Health -67.54% -13.55% -8.47%

Company	Overall Sentiment
Virax Biolabs Group	Neutral
Lucira Health	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virax Biolabs Group	$5.76 thousand	1,036.47	-$1.71 million	N/A	N/A
Lucira Health	$93.06 million	0.02	-$64.83 million	-$3.58	-0.02

Company	Underperform	Outperform
Virax Biolabs Group	N/A	N/A
Lucira Health	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virax Biolabs Group	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Lucira Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Net Margins	Return on Equity	Return on Assets
Virax Biolabs Group	N/A	N/A	N/A
Lucira Health	-67.54%	-13.55%	-8.47%

Summary

Virax Biolabs Group beats Lucira Health on 7 of the 9 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRAX vs. The Competition

Export to Excel

Metric	Virax Biolabs Group	Diagnostic substances Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.97M	$2.35B	$4.54B	$6.30B
Dividend Yield	N/A	0.79%	5.90%	6.52%
P/E Ratio	N/A	72.63	128.11	14.85
Price / Sales	1,036.47	698.23	3,489.73	96.83
Price / Cash	N/A	37.63	22.52	23.57
Price / Book	N/A	6.00	4.74	5.39
Net Income	-$1.71M	$28.14M	$117.08M	$192.60M
7 Day Performance	-1.54%	-0.51%	4.78%	3.72%
1 Month Performance	9.37%	0.12%	2.60%	5.11%
1 Year Performance	N/A	-11.29%	15.51%	2.99%

Virax Biolabs Group Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LHDXQ Lucira Health	0 of 5 stars	$0.08 -32.5%	N/A	N/A	$3.37M	$93.06M	-0.02	N/A	Upcoming Earnings Gap Down
LHDX Lucira Health	0 of 5 stars	$0.08 -32.5%	N/A	-96.8%	$3.33M	$212.13M	-0.02	114	Gap Down
NAVB Navidea Biopharmaceuticals	0 of 5 stars	$0.09 flat	N/A	N/A	$3.17M	$70,000.00	-0.18	N/A	Gap Down High Trading Volume
CDIO Cardio Diagnostics	1.9939 of 5 stars	$1.54 +4.8%	$8.00 +419.5%	N/A	$14.94M	N/A	0.00	N/A	Gap Down
SNPX Synaptogenix	0 of 5 stars	$0.82 -3.5%	N/A	-86.8%	$6.05M	N/A	-0.40	4	Positive News Gap Up
PHIO Phio Pharmaceuticals	0 of 5 stars	$4.03 -0.2%	N/A	+310.6%	$6.05M	N/A	0.00	12
OGEN Oragenics	0 of 5 stars	$2.98 -2.0%	N/A	N/A	$6.02M	$130,000.00	0.00	N/A
AVGR Avinger	1.6384 of 5 stars	$0.56 flat	N/A	-65.4%	$6.00M	$8.27M	-0.18	68
NBSE NeuBase Therapeutics	2.0703 of 5 stars	$0.18 flat	$8.50 +4,724.1%	-81.4%	$5.96M	N/A	-0.23	33	Gap Up
IGAP Integrity Applications	0 of 5 stars	$0.41 flat	N/A	-87.0%	$6.27M	N/A	0.00	11	Gap Up High Trading Volume

Related Companies and Tools

This page (NASDAQ:VRAX) was last updated on 6/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Virax Biolabs Group (VRAX) Competitors

VRAX vs. LHDXQ, LHDX, NAVB, CDIO, SNPX, PHIO, OGEN, AVGR, NBSE, and IGAP

Virax Biolabs Group vs.

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRAX vs. The Competition

Virax Biolabs Group Competitors List

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info